The Occurrence of 12 EU Priority Substances in Swiss Surface Waters and Biota – a Review of Monitoring Data
Total Page:16
File Type:pdf, Size:1020Kb
The occurrence of 12 EU priority substances in Swiss surface waters and biota – a review of monitoring data 12.9.2017 Imprint Publisher Ecotox Centre, Swiss Centre for Applied Ecotoxicology Eawag-EPFL, 8600 Dübendorf Authors Etienne Vermeirssen, Robert Kase and Ecotox Centre, Swiss Centre for Applied Ecotoxicology Inge Werner Eawag-EPFL Acknowledgements The Swiss Federal Office for the Environment (FOEN) part funded the review and commented on the re- port. FOEN also granted access to the MicroPoll Database. Monitoring data from France were provided by Valeria Dulio (INERIS) on behalf of CEP (Expert Prioritisation Committee, France, 2013). The database from the NORMAN Network “EMPODAT” was used as a valuable source of information on European monitoring data. Many other persons contributed with feedback, providing unpublished information and personal comments. Note The analyses contained in this report were conducted up to April 2014 and reflect the available data and EU Water Framework Directive Environmental Quality Standard approaches that were in use at that time. In Switzerland, intensive monitoring programmes on micropollutants were conducted within the NAWA SPEZ programme (www.bafu.admin/nawa) in 2012 and 2015 (one study is underway in 2017). Some data from 2012 are incorporated into this report, other data from 2012 and data from 2015 that are not covered here do not affect the conclusions of this report. Contact Etienne Vermeirssen: [email protected] Title optional Summary In 2000 the European Union set up the Water Framework Directive (WFD) to protect all surface and ground water resources. An integral management tool within the WFD is the implementa- tion of environmental quality standards (EQS) for priority substances. An EQS value represents the concentration of a chemical that should not be exceeded to prevent adverse effects. Three types of EQS values are used: 1) an annual average EQS (AA-EQS), to protect against long- term effects; 2) a MAC-EQS, meant to protect against short-term effect of a maximum allowable concentration (MAC); 3) a biota-EQS, to protect against indirect effects and secondary poison- ing. A first list of EQS values for 33 substances was adopted in 2008. In 2013 the EU added 12 additional substances to this list. EQS values are not only generated for EU priority substances. Individual EU member states generate EQS values for a large number of compounds that have been prioritised according to national guidelines. Within the WFD, these compounds are referred to as river basin specific pollutants. In Switzerland, the Ecotox Centre already established EQS values for more than 60 such compounds. One objective of this report is to derive EQS values for five pharmaceuticals. The main aim of this report is to summarise the exposure situation in Switzerland regarding the 12 new priority substances and the five pharmaceuticals (using available data up to April 20141). Measured concentrations of the compounds were extracted from a national database (the MicroPoll data- base) and searched in the literature. In addition, exposure data from other European countries were collected and compared with Swiss exposure data. When sufficient concentration data were available for a compound, these concentrations were compared with EQS values to eval- uate the probability of EQS exceedance. Finally, compounds were identified for which current monitoring data chemical analytical techniques are not satisfactory. The available data for the 17 compounds are very heterogeneous in terms of their quality, quan- tity and regional distribution. Nonetheless, three main conclusions can be formulated. First, chemical analysis needs to be improved to bring limits of quantification below EQS values. For some compounds this goal is within reach (PFOS, bifenox, cybutryne), for others it will remain a challenge (dicofol, cypermethrin, dichlorvos, HBCD, heptachlor). This conclusion is supported by data from adjacent countries, particularly Germany and France. Second, more water and biota monitoring is required. This involves more sampling as well as a better regional distribu- tion of sampling. Third, although the exposure data is not comprehensive or conclusive, the risk posed by the 17 compounds can be classified as: not existent, low, medium, unknown and high. The conclusions are as follows: • the five pharmaceutical for which EQS values were derived have a risk probability that is low (ciprofloxacin, propranolol) or negligible (irbesartan, valsartan, metformin) • the risk appears low for dicofol and dichlorvos and is medium for terbutryn • for lack of data, the risk posed by quinoxyfen, aclonifen, bifenox, cypermethrin, HBCD and heptachlor is classified as “unknown” • for three priority substances, the risk is high: PFOS, dioxin like PCBs and cybutryne • a number of compounds require additional monitoring: quinoxyfen, aclonifen, bifenox, PFOS and to a lesser extent this also applies to ciprofloxacin • PFOS, dioxins and dl-PCBs, HBCD, heptachlor have been banned but are of long term risk due to their persistence, continued releases from landfills and presence in sediments 1 In Switzerland, intensive monitoring programmes on micropollutants were conducted within the NAWA SPEZ programme in 2012 and 2015 (www.bafu.admin/nawa; e.g. Doppler et al. 2017). Cypermethrin data from 2012 are incorporated into this report, other data from 2012 and data from 2015 that are not covered here do not affect the conclusions of this report. iii Title optional Content Summary iii 1 Background to the Water Framework Directive and EU prioritization process ......................... 1 1.1 The Water Framework directive ........................................................................................ 1 1.2 EU priority substances ....................................................................................................... 1 1.3 Aim of the report ................................................................................................................ 2 2 Exposure and risk assessment of 12 new EU priority substances and five pharmaceuticals for Switzerland ........................................................................................................................... 3 2.1 MicroPoll database ............................................................................................................ 3 2.2 Information on exposure data from neighbouring countries, literature sources and expert feedback .......................................................................................................................... 4 2.3 Evaluating and classifying the risk of EQS exceedance ................................................... 6 2.4 Surface water and biota concentrations – exposure, risk and recommendations ............. 7 2.4.1 Dicofol AA-EQS = 1.3 ng/L ................................................................................... 7 2.4.2 PFOS AA-EQS = 0.65 ng/L or 230 ng/L .............................................................. 8 2.4.3 Quinoxyfen AA-EQS = 150 ng/L ........................................................................ 10 2.4.4 Dioxins and dioxin-like PCBs biota-EQS = 6.5 ng/kg ........................................ 11 2.4.5 Aclonifen AA-EQS = 120 ng/L ............................................................................ 12 2.4.6 Bifenox AA-EQS = 12 ng/L ................................................................................. 13 2.4.7 Cybutryne (Irgarol) AA-EQS = 2.5 ng/L ............................................................. 15 2.4.8 Cypermethrin AA-EQS = 0.08 ng/L .................................................................... 16 2.4.9 Dichlorvos AA-EQS = 0.6 ng/L ........................................................................... 17 2.4.10 Hexabromocyclododecan AA-EQS = 1.6 ng/L ................................................... 18 2.4.11 Heptachlor and Heptachlorepoxide AA-EQS = 0.0002 ng/L .............................. 19 2.4.12 Terbutryn AA-EQS = 65 ng/L ............................................................................. 20 2.4.13 Irbesartan AA-EQS = 704’000 ng/L ................................................................... 22 2.4.14 Valsartan AA-EQS = 560’000 ng/L ................................................................... 23 2.4.15 Ciprofloxacin AA-EQS = 89 ng/L ....................................................................... 24 2.4.16 Propranolol AA-EQS = 160 ng/L ........................................................................ 25 2.4.17 Metformin AA-EQS = 1’000’000 ng/L ................................................................. 26 2.5 Overall summary of exposure and risk evaluation .......................................................... 27 2.6 Conclusions ..................................................................................................................... 29 3 References .............................................................................................................................. 30 4 Glossary 37 5 Indices 38 5.1 List of Figures .................................................................................................................. 38 5.2 List of Tables ................................................................................................................... 39 Appendix 1 NORMAN Empodat data.......................................................................................... 40 iv Title optional 1 Background to